Literature DB >> 30955487

Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.

Donal McHugh1, Nicole Caduff1, Anita Murer1, Christine Engelmann1, Yun Deng1, Hana Zdimerova1, Kyra Zens1, Obinna Chijioke1, Christian Münz1.   

Abstract

Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) comprise the oncogenic human γ-herpesvirus family and are responsible for 2-3% of all tumours in man. With their prominent growth-transforming abilities and high prevalence in the human population, these pathogens have probably shaped the human immune system throughout evolution for near perfect immune control of the respective chronic infections in the vast majority of healthy pathogen carriers. The exclusive tropism of EBV and KSHV for humans has, however, made it difficult in the past to study their infection, tumourigenesis and immune control in vivo. Mice with reconstituted human immune system components (humanized mice) support replication of both viruses with both persisting latent and productive lytic infection. Moreover, B-cell lymphomas can be induced by EBV alone and KSHV co-infection with gene expression hallmarks of human malignancies that are associated with both viruses. Furthermore, cell-mediated immune control by primarily cytotoxic lymphocytes is induced upon infection and can be probed for its functional characteristics as well as putative requirements for its priming. Insights that have been gained from this model and remaining questions will be discussed in this review. This article is part of the theme issue 'Silent cancer agents: multi-disciplinary modelling of human DNA oncoviruses'.

Entities:  

Keywords:  Epstein–Barr virus; Kaposi sarcoma-associated herpesvirus; anti-viral immune control; humanized mice; lymphoma

Mesh:

Year:  2019        PMID: 30955487      PMCID: PMC6501906          DOI: 10.1098/rstb.2018.0296

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  109 in total

1.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.

Authors:  G J Babcock; D Hochberg; A D Thorley-Lawson
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

2.  Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population.

Authors:  Tonia Woodberry; Todd J Suscovich; Leah M Henry; Meredith August; Michael T Waring; Amitinder Kaur; Christoph Hess; Jeffery L Kutok; Jon C Aster; Frederick Wang; David T Scadden; Christian Brander
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

3.  IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells.

Authors:  Ester M M van Leeuwen; Godelieve J de Bree; Ester B M Remmerswaal; Si-La Yong; Kiki Tesselaar; Ineke J M ten Berge; René A W van Lier
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

4.  Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow.

Authors:  Umaimainthan Palendira; Rosanna Chinn; Wajid Raza; Karen Piper; Guy Pratt; Lee Machado; Andrew Bell; Naeem Khan; Andrew D Hislop; Richard Steyn; Alan B Rickinson; Christopher D Buckley; Paul Moss
Journal:  Blood       Date:  2008-07-17       Impact factor: 22.113

5.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

Review 6.  Pathogen-driven cancers and emerging immune therapeutic strategies.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

7.  Cognate HLA absence in trans diminishes human NK cell education.

Authors:  Vanessa Landtwing; Ana Raykova; Gaetana Pezzino; Vivien Béziat; Emanuela Marcenaro; Claudine Graf; Alessandro Moretta; Riccarda Capaul; Andrea Zbinden; Guido Ferlazzo; Karl-Johan Malmberg; Obinna Chijioke; Christian Münz
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

8.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

9.  The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events.

Authors:  Samantha K Dunmire; Jennifer M Grimm; David O Schmeling; Henry H Balfour; Kristin A Hogquist
Journal:  PLoS Pathog       Date:  2015-12-01       Impact factor: 6.823

10.  An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.

Authors:  James C Romero-Masters; Makoto Ohashi; Reza Djavadian; Mark R Eichelberg; Mitch Hayes; Jillian A Bristol; Shidong Ma; Erik A Ranheim; Jenny Gumperz; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2018-08-20       Impact factor: 7.464

View more
  10 in total

1.  Towards a multi-level and a multi-disciplinary approach to DNA oncovirus virulence.

Authors:  Samuel Alizon; Ignacio G Bravo; Paul J Farrell; Sally Roberts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

2.  CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion.

Authors:  Yun Deng; Bithi Chatterjee; Kyra Zens; Hana Zdimerova; Anne Müller; Patrick Schuhmachers; Laure-Anne Ligeon; Antonino Bongiovanni; Riccarda Capaul; Andrea Zbinden; Angelika Holler; Hans Stauss; Wolfgang Hammerschmidt; Christian Münz
Journal:  Blood       Date:  2021-06-10       Impact factor: 22.113

Review 3.  Innovations, challenges, and minimal information for standardization of humanized mice.

Authors:  Renata Stripecke; Christian Münz; Jan Jacob Schuringa; Karl-Dimiter Bissig; Brian Soper; Terrence Meeham; Leonard Shultz; Li-Chin Yao; James P Di Santo; Michael Brehm; Estefania Rodriguez; Anja Kathrin Wege; Dominique Bonnet; Silvia Guionaud; Kristina E Howard; Scott Kitchen; Florian Klein; Kourosh Saeb-Parsy; Johannes Sam; Amar Deep Sharma; Andreas Trumpp; Livio Trusolino; Carol Bult
Journal:  EMBO Mol Med       Date:  2020-06-24       Impact factor: 12.137

Review 4.  Vaccination against the Epstein-Barr virus.

Authors:  Julia Rühl; Carol S Leung; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2020-05-04       Impact factor: 9.261

5.  Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.

Authors:  Nicole Caduff; Donal McHugh; Anita Murer; Patrick Rämer; Ana Raykova; Vanessa Landtwing; Lisa Rieble; Christian W Keller; Michael Prummer; Laurent Hoffmann; Janice K P Lam; Alan K S Chiang; Friedrich Raulf; Tarik Azzi; Christoph Berger; Tina Rubic-Schneider; Elisabetta Traggiai; Jan D Lünemann; Michael Kammüller; Christian Münz
Journal:  PLoS Pathog       Date:  2020-04-06       Impact factor: 6.823

Review 6.  Redirecting T Cells against Epstein-Barr Virus Infection and Associated Oncogenesis.

Authors:  Christian Münz
Journal:  Cells       Date:  2020-06-04       Impact factor: 6.600

Review 7.  Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2019-12-17

Review 8.  Probing Reconstituted Human Immune Systems in Mice With Oncogenic γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

Review 9.  Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection.

Authors:  Christian Münz
Journal:  Biomolecules       Date:  2021-12-28

Review 10.  A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients.

Authors:  Kevin Roe
Journal:  J Neurosci Res       Date:  2021-07-19       Impact factor: 4.433

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.